Bloodlines Series: CAR T-cell Therapy Shows Promise for Smoldering Myeloma
In the CAR-PRISM clinical trial, the CAR T-cell therapy ciltacabtagene autoleucel showed promise for treating high-risk smoldering myeloma.
Tag: blood cancers
In the CAR-PRISM clinical trial, the CAR T-cell therapy ciltacabtagene autoleucel showed promise for treating high-risk smoldering myeloma.
Cancer Today's fall issue features articles on the early integration of palliative care for blood cancer patients, accommodating deaf...
This month, the AACR's journals editors highlighted studies on U.S. cancer mortality hotspots, chemotherapy-induced hearing loss, and more.
A single-cell atlas helped clarify diverse forms of acute myeloid leukemia, with potential implications for improving diagnostic, prognostic, and...
In the first quarter of 2025, the FDA issued 13 approvals for oncology treatments, covering nine types of cancer...
Multiple myeloma can be tricky to treat, but many treatment options exist, and new research is constantly supporting more.
Our annual Experts Forecast offers insights from AACR President-Elect Lillian Siu, John E. Dick, Regina Barzilay, Vinod Balachandran, and...
Amidst an FDA investigation into secondary cancers after CAR T therapy, researchers show the risk is likely minimal.
Researchers examined how the molecular features of Hodgkin lymphomas differ between young and older patients.
During his Presidential Address at the AACR Annual Meeting 2024, Philip D. Greenberg discussed research driving immunotherapy forward.